Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma ( (ASND) ) has shared an update.
Ascendis Pharma A/S reported that on March 30, 2026, the exercise window for its outstanding warrants on ordinary shares closed, resulting in the issuance of 399,438 new shares. These exercises increased the company’s nominal share capital by DKK 399,438 to DKK 62,376,846, with shares issued at an average cash consideration of about USD 92.10 per share.
The new shares, registered with the Danish Business Authority, formalize additional equity raised from warrant holders and slightly dilute existing shareholders while strengthening the company’s capital base. Ascendis updated its articles of association to reflect the higher share capital, signaling continued reliance on equity-linked incentives and financing tools within its broader capital structure.
The most recent analyst rating on (ASND) stock is a Buy with a $273.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing medical therapies for combating disease, including through innovative formulations and delivery technologies. The company manufactures and sells these medical preparations and can also hold stakes in related businesses, reflecting a strategy centered on specialty pharmaceuticals and biotech innovation.
Average Trading Volume: 679,155
Technical Sentiment Signal: Buy
Current Market Cap: $13.32B
See more data about ASND stock on TipRanks’ Stock Analysis page.